ECSP088454A - USE OF TRANSFER MODIFYING AGENTS MORE CHEMOTHERAPY OR RADIOTHERAPY AGAINST CANCER - Google Patents

USE OF TRANSFER MODIFYING AGENTS MORE CHEMOTHERAPY OR RADIOTHERAPY AGAINST CANCER

Info

Publication number
ECSP088454A
ECSP088454A ECSP088454A ECSP088454A EC SP088454 A ECSP088454 A EC SP088454A EC SP088454 A ECSP088454 A EC SP088454A EC SP088454 A ECSP088454 A EC SP088454A
Authority
EC
Ecuador
Prior art keywords
chemotherapy
radiotherapy
modifying agents
transcriptome
against cancer
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Flores Luis Estrada
Gonzalez Alfonso Duenas
Original Assignee
Univ Mexico Nacional Autonoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mexico Nacional Autonoma filed Critical Univ Mexico Nacional Autonoma
Priority to ECSP088454 priority Critical patent/ECSP088454A/en
Publication of ECSP088454A publication Critical patent/ECSP088454A/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con el uso de agentes modificantes del transcriptoma con el objetivo de impedir a las células malignas realizar los cambios génicos necesarios para hacer frente al insulto celular y sobrevivir a la quimioterapia o radioterapia. Esta combinación de modificantes del transcriptoma serán agentes que inhiban la maquinaria de metilación del DNA más una sustancia que impida las modificaciones post-transduccionales de las histonas. Se presenta un kit de tratamiento que consiste en la administración de una dosis efectiva de hidralazina más valproato de magnesio para coadyuvar con la radioterapia o quimioterapia en el tratamiento de pacientes con cáncer.The present invention relates to the use of transcriptome modifying agents in order to prevent malignant cells from making the necessary gene changes to cope with cell insult and survive chemotherapy or radiotherapy. This combination of transcriptome modifiers will be agents that inhibit DNA methylation machinery plus a substance that prevents post-transduction histone modifications. A treatment kit is presented consisting of the administration of an effective dose of hydralazine plus magnesium valproate to help with radiotherapy or chemotherapy in the treatment of cancer patients.

ECSP088454 2008-05-16 2008-05-16 USE OF TRANSFER MODIFYING AGENTS MORE CHEMOTHERAPY OR RADIOTHERAPY AGAINST CANCER ECSP088454A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ECSP088454 ECSP088454A (en) 2008-05-16 2008-05-16 USE OF TRANSFER MODIFYING AGENTS MORE CHEMOTHERAPY OR RADIOTHERAPY AGAINST CANCER

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ECSP088454 ECSP088454A (en) 2008-05-16 2008-05-16 USE OF TRANSFER MODIFYING AGENTS MORE CHEMOTHERAPY OR RADIOTHERAPY AGAINST CANCER

Publications (1)

Publication Number Publication Date
ECSP088454A true ECSP088454A (en) 2008-08-29

Family

ID=40434934

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP088454 ECSP088454A (en) 2008-05-16 2008-05-16 USE OF TRANSFER MODIFYING AGENTS MORE CHEMOTHERAPY OR RADIOTHERAPY AGAINST CANCER

Country Status (1)

Country Link
EC (1) ECSP088454A (en)

Similar Documents

Publication Publication Date Title
CO2018003678A2 (en) Compositions and methods to inhibit lpa gene expression
AR073563A1 (en) COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND RELATED STATES
ES2525759T3 (en) Means and methods for active cell immunotherapy of cancer using tumor cells destroyed by high hydrostatic pressure and dendritic cells
Xin et al. miR‑99 inhibits cervical carcinoma cell proliferation by targeting TRIB2
CR20150376A (en) REPLACED PIRROLOPIRIMIDINE COMPOUNDS, SAME COMPOUNDS AND TREATMENT METHODS WITH THE SAME
UY31543A1 (en) SYSTEM OF ADMINISTRATION OF RNAI OF INTERFERENCE AND USES OF THE SAME
CY1121838T1 (en) COMPOSITIONS COMPRISING HAPHIUM(IV) OXIDE OR RHENIUM(IV) OXIDE NANOPARTICLES IN COMBINATION WITH IONIZING RADIATION FOR THE TREATMENT OF CANCER
CO7240408A2 (en) Crystalline forms of a bruton tyrosine kinase inhibitor
BR112016029781A2 (en) compositions and methods for inhibiting alpha-1 antitrypsin gene expression
NZ585209A (en) Micro-rnas of the mir-15 family modulate cardiomyocyte survival and cardiac repair
AR080454A1 (en) PHYTOCHANABINOIDS IN THE TREATMENT OF CANCER
ECSP12011943A (en) MDPI2 ESPIRO-OXINDOL ANTAGONISTS
MX2017014641A (en) Compositions and methods for inhibiting gene expression of hif2alpha.
NI201500063A (en) CANCER TREATMENT WITH POMALIDOMIDE IN AN INDIVIDUAL WITH KIDNEY DAMAGE
PE20211961A1 (en) COMBINATION THERAPY OF RADIOIMMUNOCONJUGATES WITH DAMAGE INHIBITORS AND DNA REPAIRS
CL2020000019A1 (en) Iiarn agents for the inhibition of alpha-enac expression and methods of use.
BR112018003238A2 (en) patient selection for combination therapy
PE20200295A1 (en) MITOOCETOSCINES: THERAPEUTIC AGENTS BASED ON MITOCHONDRIA THAT TARGET KETONE METABOLISM IN CANCER CELLS
UY29901A1 (en) USE OF TRANSCRIPT MODIFYING AGENTS MORE CHEMOTHERAPY OR RADIOTHERAPY AGAINST CANCER
ECSP12011629A (en) FULVESTRANT IN A DOSE OF 500 MG FOR THE TREATMENT OF ADVANCED BREAST CANCER
CO2023016058A2 (en) RNAi agents for inhibiting mucin 5ac (muc5ac) expression, compositions thereof and methods of use
ECSP088454A (en) USE OF TRANSFER MODIFYING AGENTS MORE CHEMOTHERAPY OR RADIOTHERAPY AGAINST CANCER
Park et al. Silent mating‐type information regulation 2 homolog 1 overexpression is an important strategy for the survival of adapted suspension tumor cells
AR085399A1 (en) ANTITUMORAL COMBINATION INCLUDING CABAZITAXEL AND CISPLATINO
BR112017002166A2 (en) water buffalo-derived peptide antibiotic therapies